Research from University of Ulsan College of Medicine in the Area of Gene Therapy Described [Follow-up on phase 1 study of AT101, a novel anti-CD19 chimeric antigen receptor cell therapy (CAR-T) in patients with relapsed or refractory (r/r)...].
In: Cancer Gene Therapy Week, 2024-06-24, S. 31-31
serialPeriodical
Zugriff:
A recent study conducted by the University of Ulsan College of Medicine in Seoul, South Korea, focused on gene therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). The researchers developed a novel anti-CD19 antibody clone called AT101, which showed promising results in a phase 1 trial. The study involved 12 patients who received a single intravenous dose of AT101 at different dose levels. The results showed an overall response rate of 91.7% and a complete response rate of 75%, with a remarkable suppression of relapse after complete response. The researchers concluded that AT101 exhibited potent and enduring efficacy and a phase 2 clinical trial is currently underway for patients with diffuse large B-cell lymphoma. [Extracted from the article]
Copyright of Cancer Gene Therapy Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Research from University of Ulsan College of Medicine in the Area of Gene Therapy Described [Follow-up on phase 1 study of AT101, a novel anti-CD19 chimeric antigen receptor cell therapy (CAR-T) in patients with relapsed or refractory (r/r)...].
|
---|---|
Zeitschrift: | Cancer Gene Therapy Week, 2024-06-24, S. 31-31 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6837 (print) |
Schlagwort: |
|
Sonstiges: |
|